REDUCE

Equitas Small Finance Bank

Emkay Your success is our success

Returns to profitability, but still not out of the woods

BFSI - Banks >

Result Update >

November 02, 2025

CMP (Rs): 57 | TP (Rs): 55

After posting a loss in Q1, Equitas SFB returned to profitability with a modest PAT of Rs 241mn, supported by stable NII and controlled opex, though partly offset by lower other income and higher provisions. Credit growth remained modest at 8.5% YoY, reflecting the ongoing rundown of the MFI portfolio and the new CV segment. NIM contracted further by 26bps QoQ due to the cascading impact of the MFI portfolio decline and rate cuts. Gross slippages remained elevated at Rs6.0bn (7.1%), though strong recoveries and NPA sales to ARCs helped maintain the GNPA ratio at 2.9%—below 3%, keeping it eligible for a universal bank license. The management optimistically expects loan growth of $\sim 15\%$ in FY26 and of $\sim 20\%$ thereafter, driven by a diversified portfolio and wider product reach, while MFI stress is anticipated to ease by 4Q. Factoring in slower growth and elevated stress, we further cut our earnings; retain REDUCE and TP of Rs55, valuing the bank at 1x Sep-27E ABV. Equitas plans to raise tier I (equity capital) of Rs12.5bn to shore up its capital buffer (tier I: 16.4%).

Modest growth with further margin compression

Equitas reported a modest 8.5% YoY AUM growth, driven by a continued rundown of its MFI portfolio (now $\sim\!8\%$ of loans vs 16% YoY) and new CV segment, while non-MFI segments saw healthy growth. The bank has resumed MFI disbursements (expects Rs10bn in Q3), introduced individual MFI loans, and remains cautious on KTK with conservative credit norms. NIM contracted by 26bps QoQ to 6.3% due to the cascading impact of the MFI portfolio rundown; however, with improving MFI disbursements, lower OD flows, and funding cost benefits, yield and NIM are expected to improve and reach $\sim\!6.5\%$ by FY26 with a steady-state range of 6.5-7%. Equitas targets $\sim\!15\%$ loan growth in FY26 and $\sim\!20\%$ thereafter, aided by a diversified portfolio and broader product reach.

Stable asset quality aided by NPA sales to ARC

Gross slippages remained elevated at Rs 6.0bn (7.1%), though higher recoveries and NPA sales to ARCs helped keep the GNPA ratio stable at 2.92% (below 3%). The mgmt indicated that the MFI and non-MFI portfolios would improve from Q3, with fresh OD flows moderating (Rs300mn in Sep vs Rs240-250mn in Oct). MFI stress is projected to normalize by 4QFY26, while the bank plans to utilize the standard asset provision created in Q1FY26 over the next nine months, to manage provisions and support profitability. Credit costs are expected to remain at 1.5-1.7% in the near-to-medium term.

We retain REDUCE and TP

Factoring in the slower growth and elevated stress, we further cut our earnings estimates. We retain REDUCE with a TP of Rs55, valuing the bank at 1x Sep-27E ABV. The bank plans to raise tier I (equity capital) of Rs12.5bn to shore up its capital buffer (Tier I at 16.4%). Key upside potential to our rating: Better than expected growth/margin trajectory; earlier than expected improvement in NPA formation.

Equitas Small Financ	Equitas Small Finance Bank: Financial Snapshot (Standalone)												
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E								
Net profit	7,989	1,471	985	5,224	9,544								
Loan growth (%)	20.0	16.9	12.0	17.1	20.2								
NII growth (%)	21.0	5.6	(0.4)	20.4	20.7								
NIM (%)	8.0	6.9	6.0	6.4	6.5								
PPOP growth (%)	17.1	(3.1)	(17.8)	30.6	32.7								
Adj. EPS (Rs)	7.1	1.3	0.9	4.6	8.4								
Adj. EPS growth (%)	46.6	(81.8)	(33.2)	430.4	82.7								
Adj. BV (INR)	50.2	50.9	51.3	54.8	61.7								
Adj. BVPS growth (%)	13.2	1.5	0.8	6.7	12.6								
RoA (%)	2.0	0.3	0.2	0.8	1.3								
RoE (%)	14.4	2.4	1.6	8.3	/hite Margue								
P/E (x)	8.0	44.1	66.0	12.4	filte Marque 6.8								
P/ABV (x)	1.1	1.1	1.1	1.0	0.9								

Source: Company, Emkay Research

Target Price – 12M	Sep-26
Change in TP (%)	-
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(3.5)

Stock Data	EQUITASB IN
52-week High (Rs)	76
52-week Low (Rs)	50
Shares outstanding (mn)	1,140.5
Market-cap (Rs bn)	65
Market-cap (USD mn)	732
Net-debt, FY26E (Rs mn)	NA
ADTV-3M (mn shares)	4
ADTV-3M (Rs mn)	182.2
ADTV-3M (USD mn)	2.1
Free float (%)	99.6
Nifty-50	25,722.1
INR/USD	88.8
Shareholding,Sep-25	
Promoters (%)	0.0
FPIs/MFs (%)	15.7/48.2

Price Performance									
(%)	1M	3M	12M						
Absolute	(0.3)	(3.8)	(18.5)						
Rel. to Nifty (4.6) (7.4) (23.3)									



Anand Dama

anand.dama@emkayglobal.com +91-22-66242480

Nikhil Vaishnav

nikhil.vaishnav@emkayglobal.com +91-22-66242485

Kunaal N

kunaal.n@emkayglobal.com +91-22-66121275

Key Concall takeaways

Outlook on loans, deposits, and NIM

- Total banking sector credit to MSMEs stands at Rs22trn, with disbursements to new-to-credit (NTC) borrowers at Rs1.7trn. Equitas accounts for ~0.7% of total MSME credit exposure and contributes around 40% of the total banking-sector NTC disbursements.
- The bank has started expanding new customer acquisition in MFI. The NTB customer mix has increased to 18% in Q2FY26 from 10% in Q1FY26.
- SBL: To scale up SBL, the bank has expanded its footprint by adding around 60 new branches across AP, Tel, TN, KTK, MH, and RJ this year. Karnataka has started showing signs of improvement in net slippages. Further, disbursements have started picking up in the region.
- Vehicle Finance: To further strengthen the Used Car segment, the bank has identified ~100 high-potential existing branches and started deploying dedicated teams, ensuring focused execution and accelerated growth.
- Gold Loans: Presently, this is offered in >250 liability branches. To improve this business, the Gold loan segment is being introduced in 50 Asset branches by H2FY26. A phased roll-out in other branches will follow in FY27.
- AHF: AHF currently operates in 70 branches and is being expanded to about 30 asset branches in tier 2-5 towns by H2FY26. Further expansion to >120 asset branches will be done by FY27.
- Liabilities: The bank's Digital SA opening through the mobile app has gone live. Similarly, Digital RTD is in the pipeline and is expected to go live by Q3FY26. Strengthening sales channels across major metro markets to drive customer acquisition.
- As an extension to the flagship Elite SA program, the bank plans to introduce Elite Lite (mass-affluent product) and Elite Plus (HNI product) offerings by Q3FY26. This will complete its product suite across segments, from middle-income to HNIs.
- Yield on gross advances declined primarily due to a lower share of the MFI portfolio. No major pricing action was taken in the portfolio during Q2 or Q3.
- MFI book to be maintained at ~8–10% of the overall portfolio.
- Disbursement run rate is expected to rise further in the non-MFI segments, while the company has given guidance for MFI disbursements of around Rs10bn in Q3.
- NIM saw a decline in Q2 owing to the cascading effect of MFI stress; however, it is expected to improve from Q3 and show an uptick in Q4, supported by asset growth and funding cost benefits.
- NIM compression was driven by higher slippages and lower average quarterly advances (~Rs34.6bn in Q2FY26 vs ~Rs40bn in Q1FY26), though with improving MFI disbursements and a steady decline in the X-bucket to OD flow, yields and NIM are expected to recover from Q3 onward. NIM is projected to reach ~6.5% by FY26-end, with a steady-state range of 6.5-7.0%.

Asset quality

- Stress is seen primarily stemming from the MFI/LAP portfolio in Karnataka. However, several positive trends are visible in the MFI segment, in the industry as well as for Equitas. The share of customers with exposure to 4+ lenders in the industry reduced significantly, from 22% in Mar-24 to 10% in Sep-25.
- Collection efficiency (CE) has improved across states, including Karnataka. At the Equitas level too, slippages to the X OD bucket and 1–90 DPD category are trending down, reflecting better portfolio behavior.

In the MLAP segment, stress seen over the past two quarters was largely localized to

Karnataka, though trends have started reversing from Oct, supported by improving CE.


- Loss given default from the SBL portfolio remains NIL. The X bucket collection efficiency of new loans disbursed during the current calendar year is at the earlier normal level.
- From Aug-25, all MFI disbursements are aligned to a monthly repayment mode, enabling streamlined repayment schedules, which will further improve CE.
- Both, the MFI and non-MFI segments are expected to return to normalcy from Q4 onward, with fresh OD flows easing in MFI sequentially (Rs300mn in September vs Rs240–250mn in October).
- No impact is seen from the tariff changes; SBL stress remains largely confined to Karnataka.
- During Q2FY26, the bank sold its NPA assets (Secured Portfolio) amounting to ~Rs.2.2bn, to an ARC. Received cash recovery of Rs720mn and an asset valued at Rs1.8bn.
- Used CV portfolio: The GST-related impact is limited to early-stage loans; no effect is seen after five years. Even in October, disbursements were unaffected. For loans under three years, the impact is only 3–4%.
- Credit costs are expected in the range of 1.5–1.7% over the short-to-medium term, with a sharp decline in forward flow from fresh ODs. MFI slippage expected to improve in Q3.
- If the bank transitions to a universal bank, ECL norms will apply; however, current NPA provisioning levels are higher than ECL requirements, implying a positive impact.

Others

■ The bank targets a steady RoA of >1.5%.


Story in Charts

Exhibit 1: Credit growth moderated further due to run-down of the MFI book; deposit growth too was moderate



Source: Company, Emkay Research

Exhibit 3: Disbursements improved, led by uptick in MFI disbursement as well as improvement in the non-MFI segment




Source: Company, Emkay Research

Exhibit 5: Slippages remain elevated owing to higher MFI stress...




Source: Company, Emkay Research

Exhibit 2: The bank has built a well-diversified loan portfolio, away from MFI




Source: Company, Emkay Research

Exhibit 4: CASA ratio improved QoQ




Source: Company, Emkay Research

Exhibit 6: ...however, the sale of NPAs to an ARC enabled the bank to keep its GNPA ratio below 3%.



Source: Company, Emkay Research


Exhibit 7: DPD trends in the bank's MFI and non-MFI book are improving QoQ




Source: Company, Emkay Research

Exhibit 8: Despite elevated provisions, improved NII and controlled opex drove an uptick in ROA

Exhibit 9: We expect RoAs to gradually improve led by lower LLP





Source: Company, Emkay Research

Source: Company, Emkay Research





Source: Bloomberg, Emkay Research

Exhibit 11: Actuals vs Estimates (Q2FY26)

(Da)	A - A 1 -	Estimates		Variation		
(Rs mn)	Actuals	Emkay	Consensus	Emkay	Consensus	Comments
Net income	10,026	10,074	10,176	0% -1%		Higher NII led to stable net income
PPOP	2,406	2,323	2,648	4% -9%		Stable net income and contained opex led to a beat
PAT	241	842	331	-71%	-27%	Higher PPoP partly offset by elevated provisions led to a miss

Source: Emkay Research

Exhibit 12: Quarterly Summary

(Rs mn)	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	YoY (%)	QoQ (%)	FY25	FY26E	YoY (%)
Interest Earned	15,549	16,119	16,440	16,489	16,173	4	-2	63,117	66,605	6
Interest Expenses	7,526	7,935	8,145	8,631	8,437	12	-2	30,601	34,208	12
Net Interest Income	8,023	8,184	8,294	7,857	7,737	-4	-2	32,516	32,397	0
Global NIMs (reported)	7.7	7.4	7.1	6.6	6.3	-140bps	-26bps	6.9	6.0	-90bps
Non-interest Income	2,389	2,384	2,254	2,917	2,289	-4	-22	9,115	10,310	13
Operating Expenses	6,915	7,239	7,436	7,627	7,621	10	0	28,288	31,742	12
Pre-Provisioning Profit	3,497	3,329	3,113	3,148	2,406	-31	-24	13,343	10,965	-18
Provision & Contingencies	3,297	2,431	2,580	6,122	2,070	-37	-66	11,354	9,649	-15
PBT	201	897	533	-2,975	335	67	NA	1,988	1,316	-34
Income Tax Expense (Gain)	72	234	112	-737	94	31	NA	518	331	-36
Net Profit/(Loss)	129	663	421	-2,238	241	87	NA	1,471	985	-33
Gross NPA (%)	3.0	3.0	2.9	2.9	2.9	-3bps	0bps	2.9	2.8	-9bps
Net NPA (%)	1.0	1.0	1.0	1.0	1.0	3bps	0bps	1.0	0.9	-12bps
Deposits (Rs bn)	399	407	431	444	441	11	-1	431	484	12
Net Advances (Rs bn)	347	361	362	355	371	7	4	362	405	12

Source: Company, Emkay Research

Exhibit 13: Revision in estimates

Y/E Mar (Rs mn)	FY26E			FY27E			FY28E		
	Earlier	Revised	Change	Earlier	Revised	Change	Earlier	Revised	Change
Net income	42,662	42,707	0.1%	50,430	50,355	-0.1%	60,398	59,852	-0.9%
PPOP	11,147	10,965	-1.6%	15,065	14,325	-4.9%	20,318	19,010	-6.4%
PAT	1,583	985	-37.8%	5,523	5,224	-5.4%	10,435	9,544	-8.5%
EPS (Rs)	1.4	0.9	-37.8%	4.8	4.6	-5.5%	9.2	8.4	-8.6%
BV (Rs)	54	54	-1.0%	58	57	-1.6%	66	64	-2.6%

Source: Emkay Research

Exhibit 14: Key Assumpt	ions			
(%)	FY25	FY26E	FY27E	FY28E
Loan Growth	16.9	12.0	17.1	20.2
Deposit Growth	19.3	12.2	19.4	20.0
NIM	6.9	6.0	6.4	6.5
GNPA	2.9	2.8	2.6	2.4
Credit Cost	2.9	2.6	1.7	1.2

Source: Emkay Research

Exhibit 15: Key Ratios and Trends

	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Loans (Rs bn)	288	292	310	319	340	354	362	347	364
-Growth YoY (%)	31.7	25.5	20.0	16.0	18.1	21.1	16.9	8.8	7.0
-Growth QoQ (%)	4.5	1.5	6.0	3.1	6.4	4.2	2.3	(4.1)	4.6
Liability Profile									
Deposit (Rs bn)	308	324	361	375	399	407	431	444	441
-Growth YoY (%)	41.9	38.4	42.3	35.4	29.2	25.8	19.3	18.3	10.6
-Growth QoQ (%)	11.3	5.0	11.6	3.9	6.2	2.2	5.8	3.0	-0.6
Asset Quality (%)									
GNPA	2.3	2.5	2.6	2.7	3.0	3.0	2.9	2.9	2.9
NNPA	1.0	1.1	1.2	0.8	1.0	1.0	1.0	1.0	1.0
PCR	57.7	56.0	56.1	70.3	67.7	68.3	66.8	67.0	66.9
Slippages (Rs mn)	2,568	3,122	3,559	3,854	5,058	5,858	5,547	6,639	5,990
Slippages - Annualized	4.7	5.4	5.5	5.6	7.0	8.0	7.2	8.3	7.1
ROE Decomposition (%)									
NII	7.8	7.7	7.2	7.0	6.8	6.6	6.4	5.9	5.7
Other Income	1.9	2.0	2.2	1.8	2.0	1.9	1.7	2.2	1.7
Opex	6.3	6.2	6.0	5.8	5.8	5.8	5.7	5.7	5.6
PPOP	3.4	3.5	3.5	3.0	2.9	2.7	2.4	2.4	1.8
Provisioning Cost	0.6	0.8	1.0	2.7	2.8	2.0	2.0	4.6	1.5
PBT	2.7	2.7	2.5	0.3	0.2	0.7	0.4	(2.2)	0.2
Tax	0.7	0.7	0.6	0.1	0.1	0.2	0.1	-0.6	0.1
ROA	2.0	2.0	1.9	0.2	0.1	0.5	0.3	(1.7)	0.2
Leverage (x)	7.1	7.1	7.3	7.6	8.0	8.3	8.5	9.1	9.3
ROE	14.5	14.1	13.9	1.7	0.9	4.4	2.8	(15.3)	1.6

Source: Emkay Research

Equitas Small Finance Bank: Standalone Financials and Valuations

Balance Sheet

Profit & Loss					
Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Interest Income	54,864	63,117	66,605	76,016	87,852
Interest Expense	24,067	30,601	34,208	37,019	40,772
Net interest income	30,797	32,516	32,397	38,997	47,080
NII growth (%)	21.0	5.6	(0.4)	20.4	20.7
Other income	7,986	9,115	10,310	11,358	12,772
Total Income	38,784	41,631	42,707	50,355	59,852
Operating expenses	25,011	28,288	31,742	36,030	40,841
PPOP	13,773	13,343	10,965	14,325	19,010
PPOP growth (%)	17.1	(3.1)	(17.8)	30.6	32.7
Core PPOP	12,730	11,933	9,132	12,309	16,893
Provisions & contingencies	3,142	11,354	9,649	7,344	6,256
PBT	10,631	1,988	1,316	6,981	12,754
Extraordinary items	0	0	0	0	0
Tax expense	2,642	518	331	1,757	3,210
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
Reported PAT	7,989	1,471	985	5,224	9,544
PAT growth (%)	39.3	(81.6)	(33.0)	430.5	82.7
Adjusted PAT	7,989	1,471	985	5,224	9,544
Diluted EPS (Rs)	7.1	1.3	0.9	4.6	8.4
Diluted EPS growth (%)	46.6	(81.8)	(33.2)	430.4	82.7
DPS (Rs)	1.0	0	0.5	0.9	1.2
Dividend payout (%)	14.2	0	57.9	19.6	14.3
Effective tax rate (%)	24.8	26.0	25.2	25.2	25.2
Net interest margins (%)	8.0	6.9	6.0	6.4	6.5
Cost-income ratio (%)	64.5	68.0	74.3	71.6	68.2
Shares outstanding (mn)	1,134.9	1,139.9	1,140.5	1,140.5	1,140.5

Source: Company, Emkay Research

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	11,349	11,399	11,405	11,405	11,405
Reserves & surplus	48,336	49,327	49,741	53,939	62,114
Net worth	59,685	60,725	61,146	65,344	73,519
Deposits	361,291	431,067	483,526	577,438	693,174
Borrowings	17,875	21,370	25,644	19,233	15,386
Interest bearing liab.	379,166	452,437	509,170	596,671	708,560
Other liabilities & prov.	14,186	15,194	21,423	22,231	26,805
Total liabilities & equity	453,037	528,356	591,739	684,246	808,883
Net advances	309,643	362,089	405,420	474,908	570,780
Investments	90,653	92,887	108,136	122,658	144,382
Cash, other balances	35,789	55,363	58,555	65,634	70,856
Interest earning assets	436,085	510,339	572,111	663,200	786,018
Fixed assets	6,047	6,957	7,279	7,625	7,994
Other assets	10,905	11,061	12,348	13,421	14,872
Total assets	453,037	528,356	591,739	684,246	808,883
BVPS (Rs)	52.6	53.3	53.6	57.3	64.5
Adj. BVPS (INR)	50.2	50.9	51.3	54.8	61.7
Gross advances	314,247	369,224	413,531	483,831	580,598
Credit to deposit (%)	85.7	84.0	83.8	82.2	82.3
CASA ratio (%)	32.0	28.8	29.5	30.4	33.3
Cost of deposits (%)	7.0	7.3	7.1	6.6	6.2
Loans-to-Assets (%)	68.3	68.4	68.5	69.4	70.6
Net advances growth (%)	20.0	16.9	12.0	17.1	20.2
Deposit growth (%)	42.5	19.3	12.2	19.4	20.0
Book value growth (%)	13.2	1.3	0.6	6.9	12.5

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Asset quality					
Gross NPLs	8,212	10,677	11,587	12,748	14,026
Net NPLs	3,609	3,542	3,476	3,824	4,208
GNPA ratio (%)	2.6	2.9	2.8	2.6	2.4
NNPA ratio (%)	1.2	1.0	0.9	0.8	0.7
Provision coverage (%)	56.1	66.8	70.0	70.0	70.0
Gross slippages	11,389	20,316	22,744	14,515	12,773
Gross slippage ratio (%)	3.6	5.5	5.5	3.0	2.2
LLP ratio (%)	0.9	2.9	2.6	1.7	1.2
NNPA to networth (%)	6.0	5.7	5.6	5.7	5.6
Capital adequacy					
Total CAR (%)	21.7	20.5	18.3	16.6	15.7
Tier-1 (%)	20.7	17.8	15.9	14.5	14.0
CET-1 (%)	20.7	17.8	15.9	14.5	14.0
RWA-to-Total Assets (%)	57.4	58.5	59.0	60.0	60.0
Miscellaneous					
Total income growth (%)	30.1	14.9	6.5	13.6	15.2
Opex growth (%)	22.7	13.1	12.2	13.5	13.4
Core PPOP growth (%)	10.3	(6.3)	(23.5)	34.8	37.2
PPOP margin (%)	21.9	18.5	14.3	16.4	18.9
PAT/PPOP (%)	58.0	11.0	9.0	36.5	50.2
LLP-to-Core PPOP (%)	24.7	95.2	105.7	59.7	37.0
Yield on advances (%)	17.5	16.7	15.3	15.4	15.1
Cost of funds (%)	7.3	7.4	7.1	6.7	6.2

Source: Company, Emkay Research

Valuations and key Ratios								
Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E			
P/E (x)	8.0	44.1	66.0	12.4	6.8			
P/B (x)	1.1	1.1	1.1	1.0	0.9			
P/ABV (x)	1.1	1.1	1.1	1.0	0.9			
P/PPOP (x)	4.7	4.9	5.9	4.5	3.4			
Dividend yield (%)	1.8	0.0	0.9	1.6	2.1			
DuPont-RoE split (%)								
NII/avg assets	7.7	6.6	5.8	6.1	6.3			
Other income	2.0	1.9	1.8	1.8	1.7			
Fee income	1.7	1.6	1.5	1.5	1.4			
Opex	6.2	5.8	5.7	5.6	5.5			
PPOP	3.4	2.7	2.0	2.2	2.5			
Core PPOP	3.2	2.4	1.6	1.9	2.3			
Provisions	0.8	2.3	1.7	1.2	0.8			
Tax expense	0.7	0.1	0.1	0.3	0.4			
RoA (%)	2.0	0.3	0.2	0.8	1.3			
Leverage ratio (x)	7.2	8.2	9.2	10.1	10.8			
RoE (%)	14.4	2.4	1.6	8.3	13.7			
Quarterly data								
Rs mn	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26			
NII	8,023	8,184	8,294	7,857	7,737			
NIM (%)	7.7	7.4	7.1	6.6	6.3			
PPOP	3,497	3,329	3,113	3,148	2,406			
PAT	129	663	421	(2,238)	241			
EPS (Rs)	0.1	0.6	0.4	(2.0)	0.2			

Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
09-Aug-25	56	55	Reduce	Anand Dama
07-Jul-25	64	60	Reduce	Anand Dama
01-May-25	67	60	Reduce	Anand Dama
09-Apr-25	57	55	Reduce	Anand Dama
01-Feb-25	67	60	Reduce	Anand Dama
09-Nov-24	69	60	Reduce	Anand Dama
27-Jul-24	87	75	Reduce	Anand Dama
25-Apr-24	99	100	Reduce	Anand Dama
29-Jan-24	106	100	Reduce	Anand Dama
30-Nov-23	94	107	Add	Anand Dama

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 02, 2025
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 02, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 02, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

	· J ·····
Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.